- Blessington, Co. Wicklow
- novaerus@mcgreals.ie
- +353 (1) 255 1536
Page Rehabilitation and Healthcare Center implemented the NV200 and NV400 units in selected areas.
This study compares the average monthly rate of nosocomial respiratory infections before and after implementation of the Novaerus technology.
A 29-month review was conducted to evaluate the results of implementation.
A Nurse Risk Manager Consultant visited the facility for two days to abstract information and review the data.
In a prior review that was completed by RB Health Partners, Inc. on December 3, 2013, the average monthly rate of nosocomial respiratory infections was 20.25 before Novaerus implementation.
This prior study also observed that the averagemonthly rate of nosocomial respiratory infections decreased to 5.00 in the same four-month period after Novaerus implementation.
This study compares the average monthly rate of nosocomial respiratory infections before and after the 29-month period of implementation of the Novaerus technology.
In the 29-month period after implementation of the NV200 and NV400 in selected areas, the average monthly rate of nosocomial respiratory infections at PRHC decreased from 20.25 to 4.17, a 75.31% reduction.
About Us
Novaerus is on a mission to reduce indoor airborne pollutants that lead to infection, allergies, asthma, and odour.
The patented plasma nanotechnology used in Novaerus portable devices was invented in Ireland in 2006.
Novaerus Devices
Stay Connected to Novaerus
To keep up to date with all developments and for the latest research and scientifically proven results please follow us on LinkedIn, Facebook and Youtube.
